WO2008021183A3 - For the identification, assessment, and treatment of patients with cancer therapy - Google Patents

For the identification, assessment, and treatment of patients with cancer therapy Download PDF

Info

Publication number
WO2008021183A3
WO2008021183A3 PCT/US2007/017716 US2007017716W WO2008021183A3 WO 2008021183 A3 WO2008021183 A3 WO 2008021183A3 US 2007017716 W US2007017716 W US 2007017716W WO 2008021183 A3 WO2008021183 A3 WO 2008021183A3
Authority
WO
WIPO (PCT)
Prior art keywords
predictive markers
identification
patients
assessment
treatment
Prior art date
Application number
PCT/US2007/017716
Other languages
French (fr)
Other versions
WO2008021183A9 (en
WO2008021183A2 (en
Inventor
Barbara M Bryant
Andrew I Damokosh
George Mulligan
Original Assignee
Millennium Pharm Inc
Barbara M Bryant
Andrew I Damokosh
George Mulligan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc, Barbara M Bryant, Andrew I Damokosh, George Mulligan filed Critical Millennium Pharm Inc
Priority to EP07836670A priority Critical patent/EP2046973A4/en
Priority to JP2009523844A priority patent/JP5725711B2/en
Priority to AU2007284724A priority patent/AU2007284724B2/en
Priority to CA002660275A priority patent/CA2660275A1/en
Priority to MX2009001489A priority patent/MX2009001489A/en
Publication of WO2008021183A2 publication Critical patent/WO2008021183A2/en
Publication of WO2008021183A9 publication Critical patent/WO2008021183A9/en
Publication of WO2008021183A3 publication Critical patent/WO2008021183A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are expected to demonstrate long term or short term survival times. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with expected short term or long term survival. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine predicted patient survival.
PCT/US2007/017716 2006-08-10 2007-08-09 For the identification, assessment, and treatment of patients with cancer therapy WO2008021183A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP07836670A EP2046973A4 (en) 2006-08-10 2007-08-09 For the identification, assessment, and treatment of patients with cancer therapy
JP2009523844A JP5725711B2 (en) 2006-08-10 2007-08-09 Methods for identifying, evaluating, and treating patients with cancer treatments
AU2007284724A AU2007284724B2 (en) 2006-08-10 2007-08-09 For the identification, assessment, and treatment of patients with cancer therapy
CA002660275A CA2660275A1 (en) 2006-08-10 2007-08-09 Methods for the identification, assessment, and treatment of patients with cancer therapy
MX2009001489A MX2009001489A (en) 2006-08-10 2007-08-09 For the identification, assessment, and treatment of patients with cancer therapy.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83676406P 2006-08-10 2006-08-10
US60/836,764 2006-08-10

Publications (3)

Publication Number Publication Date
WO2008021183A2 WO2008021183A2 (en) 2008-02-21
WO2008021183A9 WO2008021183A9 (en) 2008-07-24
WO2008021183A3 true WO2008021183A3 (en) 2009-04-02

Family

ID=39082605

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/017716 WO2008021183A2 (en) 2006-08-10 2007-08-09 For the identification, assessment, and treatment of patients with cancer therapy

Country Status (7)

Country Link
US (1) US9500656B2 (en)
EP (1) EP2046973A4 (en)
JP (1) JP5725711B2 (en)
AU (1) AU2007284724B2 (en)
CA (1) CA2660275A1 (en)
MX (1) MX2009001489A (en)
WO (1) WO2008021183A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120004854A1 (en) * 2008-05-28 2012-01-05 Georgia Tech Research Corporation Metabolic biomarkers for ovarian cancer and methods of use thereof
US20110190157A1 (en) * 2008-08-15 2011-08-04 The Regents Of The University Of California Biomarkers for Diagnosis and Treatment of Chronic Lymphocytic Leukemia
US20120149647A1 (en) * 2009-03-17 2012-06-14 Brody Jonathan R Methods for Assessing the Efficacy of Gemcitabine or Ara-C Treatment of Cancer Using Human Antigen R Levels
EP2419111A4 (en) * 2009-04-17 2013-01-02 Univ Health Network Uhn Sensitizing agents for cancer therapy, methods of use and methods for the identification thereof
US20100280987A1 (en) * 2009-04-18 2010-11-04 Andrey Loboda Methods and gene expression signature for assessing ras pathway activity
US7615353B1 (en) * 2009-07-06 2009-11-10 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
EP2486154B1 (en) * 2009-10-08 2017-03-01 Wake Forest University Health Sciences Diagnostic and prognostic markers for cancer
NZ617003A (en) * 2010-01-11 2015-04-24 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
EP2606349A4 (en) * 2010-08-20 2014-04-30 Univ Jefferson Cancer diagnostic and cancer therapeutic
WO2013023132A1 (en) 2011-08-10 2013-02-14 Wake Forest University Health Sciences Diagnostic and prognostic markers for cancer
JP6002222B2 (en) 2011-08-11 2016-10-05 ヤンセン ファーマシューティカ エヌ．ベー． Cancer treatment predictors
US10085987B2 (en) 2012-01-27 2018-10-02 Thomas Jefferson University MCT protein inhibitor-related prognostic and therapeutic methods
PL3387898T3 (en) * 2013-03-15 2020-10-19 Mayo Foundation For Medical Education And Research Identification and monitoring of monoclonal immunoglobulins by molecular mass
US10022372B2 (en) 2013-04-19 2018-07-17 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
EP3004392B1 (en) 2013-05-30 2020-09-30 Genomic Health, Inc. Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
US20150287143A1 (en) * 2014-04-03 2015-10-08 John Hancock Life Insurance Company (U.S.A.) System and method for managing underwriting using a risk order approach
JP6759104B2 (en) 2014-04-04 2020-09-23 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Immunoglobulin isotyping using precise molecular mass
JP6675990B2 (en) * 2014-05-20 2020-04-08 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム How to treat multiple myeloma
EP3175242A4 (en) 2014-07-29 2017-12-27 Mayo Foundation for Medical Education and Research Quantifying monoclonal antibody therapeutics by lc-ms/ms
EP3353200A4 (en) 2015-09-24 2019-06-26 Mayo Foundation for Medical Education and Research Identification of immunoglobulin free light chains by mass spectrometry
JP6681475B2 (en) * 2015-10-26 2020-04-15 サイフェローム Customized drug selection method and system using genomic nucleotide sequence mutation information and survival information of cancer patients
EP3523647B1 (en) 2016-09-07 2024-06-26 Mayo Foundation for Medical Education and Research Identification and monitoring of cleaved immunoglobulins by molecular mass
WO2018201083A1 (en) * 2017-04-28 2018-11-01 University Of Southern California System and method for predicting survival time
WO2019055634A1 (en) 2017-09-13 2019-03-21 Mayo Foundation For Medical Education And Research Identification and monitoring of apoptosis inhibitor of macrophage
CN110108878A (en) * 2019-05-30 2019-08-09 四川大学华西医院 EIF2S1 autoantibody detection reagent is preparing the purposes in screening lung cancer kit

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05296999A (en) * 1992-04-24 1993-11-12 Amano Pharmaceut Co Ltd Human lipocortin i as marker for discriminating effect of flucocorticoid and its determining method
JP2004248502A (en) * 2000-10-05 2004-09-09 Takara Holdings Inc Method for evaluating malignancy of cancer
CA2481485A1 (en) * 2002-04-04 2003-10-16 Ishihara Sangyo Kaisha, Ltd. Apparatus and method for analyzing data
WO2004053066A2 (en) * 2002-12-06 2004-06-24 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
US20040191782A1 (en) * 2003-03-31 2004-09-30 Yixin Wang Colorectal cancer prognostics
US7741035B2 (en) * 2004-05-21 2010-06-22 Board Of Trustees Of The University Of Arkansas Use of gene expression profiling to predict survival in cancer patient
CA2611728A1 (en) * 2005-06-08 2006-12-14 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BALL ET AL.: "Neuron specific Hel-N1 and HUD as novel molecular markers of neuroblastoma: A correlation of HUD messenger RNA levels with favorable prognostic features", CLIN CANCER RES, vol. 3, October 1997 (1997-10-01), pages 1859 - 1865, XP008107830 *
See also references of EP2046973A4 *

Also Published As

Publication number Publication date
US20080064055A1 (en) 2008-03-13
EP2046973A2 (en) 2009-04-15
US9500656B2 (en) 2016-11-22
WO2008021183A9 (en) 2008-07-24
JP2010500565A (en) 2010-01-07
CA2660275A1 (en) 2008-02-21
AU2007284724A1 (en) 2008-02-21
AU2007284724B2 (en) 2014-03-13
WO2008021183A2 (en) 2008-02-21
JP5725711B2 (en) 2015-05-27
MX2009001489A (en) 2009-02-18
EP2046973A4 (en) 2010-04-07

Similar Documents

Publication Publication Date Title
WO2008021183A3 (en) For the identification, assessment, and treatment of patients with cancer therapy
WO2006133420A3 (en) Treatment of patients with cancer therapy
EP1994181A4 (en) Identification and use of novopeptides for the treatment of cancer
WO2010017515A3 (en) Breast cancer specific markers and methods of use
EP2272453A4 (en) Therapy system, therapy instrument and method of treating living tissues with the use of energy
EP1985302A4 (en) Medicament for treatment of tumor and the use thereof
GB0804401D0 (en) For treatment of adipose tissue, cutaneous tissue and disorders, and muscular tissue
GB2439393B (en) Cannabinoids for use in the treatment of neuropathic pain
EP2173740A4 (en) Heme-oxygenase inhibitors and use of the same in the treatment of cancer and diseases of the central nervous system
MX2012001716A (en) Biological markers for monitoring patient response to vegf antagonists.
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
WO2009026657A8 (en) Flavonoid ppar agonists
IL196077A0 (en) Appatatus and method for stimulation of biological tissue
EP2019649A4 (en) Compositions and methods for treating or preventing diseases of body passageways
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
IL202674A0 (en) Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma
EP2527466A3 (en) Genetic variants on CHR2 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
IL210439A0 (en) Genetic variants as markers for use in urinary bladder cancer risk assessment, diagnosis, prognosis and treatment
EP2074661A4 (en) Use of quantum system identification and quantum control techniques for medical diagnostic and therapeutic purposes
EP2136814A4 (en) Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture
MX2009005941A (en) Companion diagnostic assays for cancer therapy.
EP2012798A4 (en) Use of inositol-tripyrophosphate in treating tumors and diseases
WO2010074936A3 (en) Enzastaurin for the treatment of cancer
IL204584A0 (en) Compounds for use in imaging, diagnosing, and/or treatment of diseases of the central nervous system or of tumors
HK1150401A1 (en) Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07836670

Country of ref document: EP

Kind code of ref document: A2

REEP Request for entry into the european phase

Ref document number: 2007836670

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007836670

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2660275

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007284724

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2009523844

Country of ref document: JP

Ref document number: MX/A/2009/001489

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007284724

Country of ref document: AU

Date of ref document: 20070809

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: RU